Skip to main content
. 2023 Sep 25;2(8):100622. doi: 10.1016/j.jacadv.2023.100622

Figure 3.

Figure 3

Pharmacologic Effects of Disopyramide on the Pathomechanism of Obstructive Hypertrophic Cardiomyopathy

This drug decreases LVOT obstruction by mitigating the effects of energy-wasting hypercontractility in HCM by blocking the sodium channels on cardiomyocytes, leading to a decrease in sodium-calcium exchanger activity, causing a fall in intracardiomyocyte calcium levels. HCM = hypertrophic cardiomyopathy; LVOT = left ventricular outflow tract.